As an Investing Associate, Brian evaluates investment opportunities, manages due diligence, and supports Serent’s portfolio companies.
Prior to Serent, Brian was an Investment Banking Analyst at J.P. Morgan, where he supported various transactions across the healthcare space, including BioMarin’s activist defense and the IPOs of Kyverna Therapeutics, Upstream Bio and Ceribell.
Brian holds a B.B.A. in Finance from The University of Texas at Austin.
Brian is a proud Texan who defends Whataburger and Dr Pepper fiercely and enjoys exploring new restaurants, playing volleyball, and frequenting the SF Symphony.
This publication is for informational purposes only, and nothing contained herein constitutes an offer to sell or a solicitation of an offer to buy any interest in any investment vehicle managed by Serent Capital or any company in which Serent Capital or its affiliates have invested. An offer or solicitation will be made only through a final private placement memorandum, subscription agreement and other related documents with respect to a particular investment opportunity and will be subject to the terms and conditions contained in such documents, including the qualifications necessary to become an investor. Serent Capital does not utilize its website to provide investment or other advice, and nothing contained herein constitutes a comprehensive or complete statement of the matters discussed or the law relating thereto. Information provided reflects Serent Capital’s views as of a particular time and are subject to change without notice. You should obtain relevant and specific professional advice before making any investment decision.
Certain information on this Website may contain forward-looking statements, which are subject to risks and uncertainties and speak only as of the date on which they are made. The words “believe”, “expect”, “anticipate”, “optimistic”, “intend”, “aim”, “will” or similar expressions are intended to identify forward-looking statements. Serent Capital undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Past performance is not indicative of future results; no representation is being made that any investment or transaction will or is likely to achieve profits or losses similar to those achieved in the past, or that significant losses will be avoided.
